Add to ORKGSurgical resection remains the treatment of choice for patients with early localised non-small cell lung carcinoma (NSCLC) with results showing five-year survival rates of approximately 50 % for clinically stage
A national, evidence-based guideline on the staging and treatment of patients with non-small cell lu...
We discussed in this article about the role of surgery, in a broad sense, and radiotherapy for the t...
Definitive radiochemotherapy is the standard treatment for many patients with locally advanced nonsm...
The aim of this paper is to review the experience of radical radiation therapy and the prognostic fa...
The incidence of stage I and II nonsmall cell lung cancer is likely to increase with the ageing popu...
The incidence of stage I and II nonsmall cell lung cancer is likely to increase with the ageing popu...
Objective: Determine the clinical effectiveness of definitive treatment for non-small cell lung canc...
AbstractLung cancer is among the most common cancers worldwide and is the leading cause of cancer de...
Non-small cell lung cancer (NSCLC) is an inherently insensetive tumor to many types of treatment. In...
Surgery represents the best treatment for early-stage non-small-cell lung cancer (NSCLC). In selecte...
Lung cancer is one of the leading causes of death worldwide, and it is the largest contributor to ne...
We aimed to review the development of the chemoradiotherapy options used in the treatment of locally...
Definitive radiochemotherapy is the standard treatment for many patients with locally advanced nonsm...
Lung cancer is the most frequent cause of cancer death in both men and women in North America. In 20...
To determine the overall survival, progression-free survival, and toxicity associated with concurren...
A national, evidence-based guideline on the staging and treatment of patients with non-small cell lu...
We discussed in this article about the role of surgery, in a broad sense, and radiotherapy for the t...
Definitive radiochemotherapy is the standard treatment for many patients with locally advanced nonsm...
The aim of this paper is to review the experience of radical radiation therapy and the prognostic fa...
The incidence of stage I and II nonsmall cell lung cancer is likely to increase with the ageing popu...
The incidence of stage I and II nonsmall cell lung cancer is likely to increase with the ageing popu...
Objective: Determine the clinical effectiveness of definitive treatment for non-small cell lung canc...
AbstractLung cancer is among the most common cancers worldwide and is the leading cause of cancer de...
Non-small cell lung cancer (NSCLC) is an inherently insensetive tumor to many types of treatment. In...
Surgery represents the best treatment for early-stage non-small-cell lung cancer (NSCLC). In selecte...
Lung cancer is one of the leading causes of death worldwide, and it is the largest contributor to ne...
We aimed to review the development of the chemoradiotherapy options used in the treatment of locally...
Definitive radiochemotherapy is the standard treatment for many patients with locally advanced nonsm...
Lung cancer is the most frequent cause of cancer death in both men and women in North America. In 20...
To determine the overall survival, progression-free survival, and toxicity associated with concurren...
A national, evidence-based guideline on the staging and treatment of patients with non-small cell lu...
We discussed in this article about the role of surgery, in a broad sense, and radiotherapy for the t...
Definitive radiochemotherapy is the standard treatment for many patients with locally advanced nonsm...